MS Diagnosis in the US show that nearly 1 million adults (913,925) live with multiple sclerosis in 2026, with roughly 10,000 to 23,000 new diagnoses each year and no national registry to count them exactly. Women make up 76% of cases, most people receive a diagnosis between ages 20 and 50, and a 2025 US registry study found a median diagnostic delay of 2.0 months but a mean of 22.8 months.
MS Diagnosis in the US 2026 – Introduction
MS Diagnosis Statistics in the US rest on estimates, not a headcount. No national registry records every new case of multiple sclerosis. The National Multiple Sclerosis Society, the CDC and university researchers fill the gap with insurance-claims analysis, surveys and registry studies. Each method counts a slightly different group, so the numbers differ by source.
This report gathers the latest verified figures through October 2026. It draws on the National MS Society prevalence study, a 2023 JAMA Neurology analysis from Stanford University, the 2026 Atlas of MS, two 2025 studies of diagnostic delay, and the 2024 McDonald criteria. Every table lists its source and its limits.
Interesting Facts About MS Diagnosis Statistics in the US 2026
MS FACTS SNAPSHOT: KEY SHARES (%)
Women among US cases ████████████████████████████████████████ 76
Relapsing MS at diagnosis ███████████████████████████████████░░░░░ 85
Primary progressive (high) ██████░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░ 15
| Metric | Latest Data Point |
|---|---|
| Adults living with MS in the US | 913,925 |
| Earlier estimate replaced | 300,000–400,000 |
| New diagnoses per year (estimates vary) | 10,000–23,000 |
| Women share of US cases | 76% |
| Women-to-men ratio | 2.9 |
| Typical age at diagnosis | 20–50 |
| Average age at diagnosis | About 29 |
| Relapsing MS at diagnosis | About 85% |
| Primary progressive MS at diagnosis | 10%–15% |
| US median diagnostic delay (2025 registry) | 2.0 months |
| People with MS worldwide (2026) | 3.1 million |
Data source: National Multiple Sclerosis Society; Multiple Sclerosis International Federation, Atlas of MS (2026); JAMA Neurology (2023); Vanderbilt University Medical Center; Multiple Sclerosis Journal – Experimental, Translational and Clinical (2025).
The headline number is 913,925 adults, from the National MS Society’s prevalence study. It replaced an older 300,000–400,000 estimate that rested on dated data. Annual new cases remain uncertain, which is why this report shows a 10,000–23,000 range instead of one figure. The MS Diagnosis Statistics in the US on new cases depend on which survey you trust.
The remaining rows describe who gets diagnosed and how, and they draw on peer-reviewed work from 2019 through 2025. Women account for 76% of cases, a ratio of 2.9 women per man. Most diagnoses land between ages 20 and 50, and about 85% begin as relapsing MS. The 2.0-month median delay looks short. The mean of 22.8 months shows that a minority of patients wait years.
MS Diagnosis Statistics in the US 2026: New Cases Per Year by Source
ESTIMATED NEW MS DIAGNOSES PER YEAR, US
American Brain Foundation ███████████░░░░░░░░░░░░░ 10,000
MS Discovery Forum (200/wk) ███████████░░░░░░░░░░░░░ 10,400
Atlas of MS (450+/wk) ████████████████████████ 23,400
| Source | Reported Figure | Annual Equivalent |
|---|---|---|
| American Brain Foundation | 10,000 per year | 10,000 |
| MS Discovery Forum | 200 per week | 10,400 (report calculation) |
| Atlas of MS (2022 data) | 450+ per week | 23,400 (report calculation) |
Data source: American Brain Foundation; MS Discovery Forum, as cited by Healthline; Multiple Sclerosis International Federation, Atlas of MS, as cited by SingleCare. Annual equivalents are report calculations.
Three sources, two answers. The American Brain Foundation reports 10,000 new cases a year, and the MS Discovery Forum’s weekly figure of 200 works out to 10,400. The Atlas of MS cites more than 450 new diagnoses per week, or about 23,400 a year. Those weekly figures come from different counting methods, not from a real surge.
No registry settles the gap. The CDC built the National Neurological Conditions Surveillance System to improve data on MS and other neurological conditions, and it published updated prevalence estimates through that system in 2023. Insurance-claims algorithms, patient surveys and advocacy-group estimates all feed these totals. Until surveillance matures, treat 10,000 as the conservative floor and 23,400 as the high estimate in MS Diagnosis Statistics in the US.
How Many Americans Have MS in 2026? US and Global Prevalence
PEOPLE LIVING WITH MS (THOUSANDS)
US earlier estimate (high) ██████████████░░░░░░░░░░░░░░░░ 400
US prevalence study ██████████████████████████████ 913.9
| Measure | Value |
|---|---|
| US adults living with MS (NMSS study) | 913,925 |
| Earlier US estimate | 300,000–400,000 |
| US adult MS cases, 2008–2010 claims | 744,781 |
| People with MS worldwide (2026 Atlas) | 3.1 million |
| Global prevalence rate | 38 per 100,000 |
| Global prevalence, 2020 | 2.8 million |
Data source: National Multiple Sclerosis Society prevalence workgroup; Neurology (2019); JAMA Neurology (2023); Multiple Sclerosis International Federation, Atlas of MS (2026).
The prevalence study found 913,925 adults living with MS, more than double the 300,000–400,000 older estimate. The 744,781 figure comes from the Stanford analysis of 2008–2010 claims data, which feeds the demographic tables later in this report. The gap between 744,781 and 913,925 reflects different years and methods, not a measurement error.
The Atlas of MS 2026 counts 3.1 million people with MS worldwide, up from 2.8 million in 2020. That equals 38 per 100,000 people, or about 1 in 2,600. The CDC surveillance system and the National MS Society workgroup remain the two main US sources. The Atlas places the United States at the top of its prevalence ranking by a wide margin. The US total of 913,925 therefore equals roughly 29% of the global count (report calculation). Both totals are estimates, and the Atlas notes that most of its figures come directly from national reports.
MS Diagnosis Statistics in the US 2026 by Gender: Women vs Men
MS BY GENDER AND DELAY
Women share of cases (%) ████████████████████████████████████████ 76
Men share of cases (%) ████████████░░░░░░░░░░░░░░░░░░░░░░░░░░░░ 24
Median delay, women (months) ███████░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░ 5
Median delay, men (months) ████████████████████████░░░░░░░░░░░░░░░░ 16.5
| Metric | Women | Men |
|---|---|---|
| Share of US adult cases | 76% (564,426) | 24% |
| Women-to-men ratio | 2.9 | — |
| Median delay, symptom onset to diagnosis | 5 months | 16.5 months |
| Share of 2019–2021 clinic survey sample | 76.3% | 23.7% |
Data source: JAMA Neurology (2023), Stanford University School of Medicine; Journal of Racial and Ethnic Health Disparities (2025), Georgetown University and University of Virginia clinicians.
Women made up 76% of the 744,781 adults identified in the 2023 JAMA Neurology analysis, which equals 564,426 women. The overall ratio was 2.9 women for every man. The 2019–2021 clinic survey sampled 245 patients and found a nearly identical 76.3% share of women. Two independent datasets agree on the gender split, which supports the 2.9 ratio as a stable benchmark for MS Diagnosis Statistics in the US.
Men wait longer. The clinic survey found a median delay of 16.5 months for men and 5 months for women (p = 0.015). Men also tended to be older at diagnosis. The authors note that these delays can feed the perception that MS runs a more aggressive course in men. Because the survey came from one center, MS Diagnosis Statistics in the US on gender delay need confirmation in larger samples.
MS Diagnosis Statistics in the US 2026 by Age: When Do People Get Diagnosed?
MS CASES BY AGE GROUP, US ADULTS (%)
Youngest adult group ███████░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░ 14
Ages 35-44 ██████████░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░ 21
Ages 45-54 ███████████████░░░░░░░░░░░░░░░░░░░░░░░░░ 31
Ages 55-64 ████████████░░░░░░░░░░░░░░░░░░░░░░░░░░░░ 25
Ages 65+ ████░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░ 9
| Age Group | Share of US Adult MS Cases |
|---|---|
| Youngest adult group | 14% |
| Ages 35–44 | 21% |
| Ages 45–54 | 31% |
| Ages 55–64 | 25% |
| Ages 65 and older | 9% |
Data source: JAMA Neurology (2023), Stanford University School of Medicine; National Multiple Sclerosis Society; Vanderbilt University Medical Center.
This table shows who lives with MS, not who receives a new diagnosis. Ages 45–54 hold the largest share at 31%, and the highest prevalence in the study sat in the 45–64 group. People diagnosed in their twenties and thirties age into those brackets. Cases under age 35 make up only 14%, and 9% are 65 or older.
New diagnoses skew younger. The National MS Society says most people are diagnosed between ages 20 and 50. Vanderbilt clinicians put the average at about 29 and say pediatric-onset cases are about 5% of the total. Researchers estimate between 5,000 and 10,000 children and teens live with MS in the US. Age is the strongest filter inside MS Diagnosis Statistics in the US, because it shapes who gets tested, who gets referred and how fast each step happens.
MS Type at Diagnosis in the US 2026: Relapsing vs Progressive Disease
MS COURSE AT DIAGNOSIS (%)
Relapsing MS (about) █████████████████████████████████████████ 85
Primary progressive (high) ██████░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░ 15
Pediatric-onset share (about) ███░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░ 5
| Indicator | Value |
|---|---|
| Relapsing MS at diagnosis | About 85% |
| Primary progressive MS at diagnosis | 10%–15% |
| Pediatric-onset share of cases | About 5% (range 2%–10%) |
| Children and teens with MS in the US | 5,000–10,000 |
| Brain lesions leading to MS within a few years | 60%–80% |
| Cases first seen at age 50 or older | About 5% |
Data source: National Multiple Sclerosis Society, as cited by Healthline; Vanderbilt University Medical Center; Americas Committee for Treatment and Research in MS, as reported by Cleveland Clinic; Multiple Sclerosis Association of America.
Most patients start with the relapsing form. About 85% receive a relapsing diagnosis, and 10%–15% begin with primary progressive MS, which builds disability steadily from the start. The split matters for MS Diagnosis Statistics in the US because progressive onset takes longer to confirm. A 2025 multicenter study in BMC Neurology of 239 patients found the same pattern, with primary progressive patients waiting about 19 months on average.
Age creates two smaller groups. Pediatric-onset MS makes up about 5% of cases, with published estimates from 2% to 10%, and most children are older than 10. Another 5% of patients are first seen at age 50 or older, which is why the 2024 criteria added guidance for that group. The National MS Society reports a 60%–80% chance of an MS diagnosis within a few years for people whose scans show brain lesions.
MS Diagnostic Delay in the US 2026: How Long Does Diagnosis Take?
DIAGNOSTIC DELAY, US REGISTRY STUDY (MONTHS)
Median delay █░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░ 2.0
Mean delay ███████████████████░░░░░░░░░░░░░░░░░░░░░ 22.8
Median, earlier unchecked signs ████████████████████████████████████████ 64.8
| Metric | Value |
|---|---|
| Patients in registry survey | 428 |
| Median delay, symptom to diagnosis | 2.0 months |
| Mean delay | 22.8 months |
| Longest delay recorded | 32.9 years |
| Reported symptoms misdiagnosed | 40.4% (173 of 428) |
| Earlier symptoms never evaluated | 50.7% |
| Median delay counting those symptoms | 5.4 years |
Data source: Multiple Sclerosis Journal – Experimental, Translational and Clinical (2025), Solomon et al.; American Journal of Managed Care reporting on the same study. The 64.8-month chart value is a report calculation (5.4 years x 12).
The 2025 registry study found a median delay of 2.0 months, yet the mean reached 22.8 months because a few patients waited decades. The longest wait was 32.9 years. About 40.4% of respondents said clinicians first misread symptoms later traced to MS, and that group faced longer delays. Delay shrank over time as the diagnostic criteria changed.
The timeline stretches when patients count earlier symptoms. About 50.7% reported MS-related symptoms that no clinician ever evaluated, and the median delay from those signs to diagnosis was 5.4 years. Other neurological diseases show similar lags. A separate report on ALS statistics in the US puts the average wait from first symptoms to a confirmed ALS diagnosis at 12–18 months. Black patients in the clinic survey also waited at least 6 months longer to see a neurologist, and men and Black patients tended to present with more disabling symptoms at diagnosis.
MS Prevalence in the US 2026 by Race, Ethnicity and Latitude
MS PREVALENCE PER 100,000 US ADULTS (2010 ESTIMATE)
White ████████████████████████████████████████ 374.8
Black ████████████████████████████████░░░░░░░░ 298.4
Other groups █████████████████████░░░░░░░░░░░░░░░░░░░ 197.7
Hispanic █████████████████░░░░░░░░░░░░░░░░░░░░░░░ 161.2
| Group | Prevalence per 100,000 | Share of Cases |
|---|---|---|
| White | 374.8 | 77% |
| Black | 298.4 | 10% |
| Hispanic | 161.2 | 7% |
| Other racial and ethnic groups | 197.7 | 4% |
Data source: JAMA Neurology (2023), Hittle et al., funded by the National Multiple Sclerosis Society.
White Americans show the highest prevalence at 374.8 per 100,000 and account for 77% of cases. Black Americans follow at 298.4 and 10% of cases. Hispanic Americans show 161.2 per 100,000, the lowest rate. People in the “other” group, which includes Asian, Native American and multiracial adults, show 197.7. These rates describe prevalence in 2010, not new diagnoses, and they accumulate years of claims data, so they reflect existing diagnoses.
Geography matters as well. Prevalence rose by 16.3 cases per 100,000 for each degree of latitude in unadjusted estimates and by 11.7 after adjustment. The link was strongest in women, Black adults and older adults. MS is one piece of the nation’s neurological load, and the brain health statistics in the US show how conditions from stroke to dementia compete for the same specialist capacity.
MS Diagnosis Criteria in the US 2026: The 2024 McDonald Update
CNS AREAS USABLE FOR DISSEMINATION IN SPACE
2017 McDonald criteria ████████████████░░░░ 4
2024 McDonald criteria ████████████████████ 5
| Change | 2024 McDonald Criteria |
|---|---|
| Publication | Lancet Neurology, September 2025 |
| Previous revision | 2017 |
| Optic nerve | Added as fifth CNS location |
| Kappa free light chains | Accepted instead of oligoclonal bands |
| Central vein sign | Supportive MRI evidence |
| Paramagnetic rim lesions | Supportive MRI evidence |
| Age guidance | Adds guidance for ages 50 and older |
Data source: The Lancet Neurology (2025), International Advisory Committee on Clinical Trials in Multiple Sclerosis; ECTRIMS; National Multiple Sclerosis Society.
The 2024 revisions mark the fifth update since the criteria first appeared in 2001, and the first major change since 2017. The optic nerve now counts as a fifth location for showing lesions in different parts of the central nervous system. The kappa free light chain index can replace oligoclonal bands as proof of timing. Optic neuritis already counted under the older rules, but silent optic nerve lesions on MRI now count too. The authors expect the changes to speed diagnosis while keeping specificity.
The new criteria also accept the central vein sign and paramagnetic rim lesions as supportive MRI evidence. They add guidance for patients aged 50 and older and for those with other conditions. Doctors still must rule out other diagnoses first. MS counts among the nation’s autoimmune diseases in the US, a group that a separate report on this site puts at 15.4 million diagnosed Americans. The criteria change only affects future diagnoses, not existing ones.
MS Diagnosis Statistics in the US 2026 FAQ
How Many People Are Diagnosed With MS in the US Each Year in 2026?
Estimates run from about 10,000 to 23,400 per year. No national registry counts every case, so sources use different methods.
How Many Americans Have MS in 2026?
The National MS Society’s prevalence study counted 913,925 adults. That figure is more than double the older 300,000–400,000 estimate.
What Is the Average Age of MS Diagnosis in the US in 2026?
Vanderbilt clinicians cite an average of about 29. Most people are diagnosed between ages 20 and 50.
What Percentage of MS Patients Are Women in 2026?
Women made up 76% of the 744,781 adult cases in the 2023 JAMA Neurology analysis. The women-to-men ratio was 2.9.
How Long Does It Take to Get an MS Diagnosis in the US in 2026?
A 2025 US registry study found a median of 2.0 months and a mean of 22.8 months. About 40.4% of patients reported an earlier misdiagnosis of symptoms.
Do Men Wait Longer for an MS Diagnosis in 2026?
One clinic survey found a median delay of 16.5 months for men and 5 months for women. The study came from a single institution.
What Type of MS Do Most People Have at Diagnosis in 2026?
About 85% begin with relapsing MS. Primary progressive MS affects 10%–15% at diagnosis.
Is MS More Common in Northern States in 2026?
Yes. Prevalence rose by 16.3 cases per 100,000 for each degree of latitude in unadjusted estimates.
What Changed in the 2024 McDonald Criteria for MS in 2026?
The criteria added the optic nerve as a fifth diagnostic location. They also accepted kappa free light chains and new MRI markers as supportive evidence.
How Many Children in the US Have MS in 2026?
Estimates range from 5,000 to 10,000 children and teens. Pediatric-onset MS is about 5% of all cases.
Does the MS Diagnosis Process Differ After Age 50 in 2026?
Yes. The 2024 McDonald criteria add guidance for patients aged 50 and older and for those with other conditions. About 5% of cases are first seen at that age.
Do Brain Lesions Always Mean MS in 2026?
No. The National MS Society reports a 60%–80% chance of an MS diagnosis within a few years for people with brain lesions.
How Many People Have MS Worldwide in 2026?
The 2026 Atlas of MS counts 3.1 million people, or 38 per 100,000.
Disclaimer: This research report is compiled from publicly available sources. While reasonable efforts have been made to ensure accuracy, no representation or warranty, express or implied, is given as to the completeness or reliability of the information. We accept no liability for any errors, omissions, losses, or damages of any kind arising from the use of this report.